The NLCFN has been contacted by the trial coordinator for the SARON trial based at CRUK &; UCL Cancer Trials Centre (UCL CTC) in London. They are looking at opportunities to promote this national lung trial. The trial is funded by CRUK, sponsored by UCL and coordinated at UCL CTC. The Chief Investigator of this trial is Dr David Lindau. Currently, there are 12 centres throughout the UK with an aim of having about 30 centres in total. Information about the trial can be viewed at: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-stereotactic-ablative-radiotherapy-for-non-small-cell-lung-cancer-saron The trial patient population is stage IV non small cell lung cancer, with metastatic disease (not more than 3 areas). SARON is a randomised trial where patients will have either chemotherapy only (standard) or chemotherapy plus radiotherapy (it could be conventional radiotherapy, or stereotactic ablative radiotherapy (SABR) and/or stereotactic radiosurgery (SRS).